Skip to main content

Table 3 Cox regression analysis of radiographic progression in patients treated with post-prostatectomy radiotherapy (n = 81) who experienced biochemical recurrence after radiotherapy

From: Androgen deprivation therapy during and after post-prostatectomy radiotherapy in patients with prostate cancer: a case control study

 

Univariate analysis

Multivariate analysis

HR (95% CI)

p-value

HR (95% CI)

p-value

Age (years)

1.035 (0.978–1.096)

0.231

  

BMI (kg/m2)

0.913 (0.773–1.078)

0.282

  

Pre-operative PSA (ng/mL)

  < 20.00

(reference)

   

  ≥ 20.00

1.111 (0.551–2.241)

0.768

  

Pre-radiotherapy PSA (ng/mL)

  < 1.00

(reference)

   

  ≥ 1.00

0.906 (0.427–1.923)

0.796

  

Pathologic Gleason score

  ≤ 7

(reference)

 

(reference)

 

  ≥ 8

2.438 (1.169–5.084)

0.017

1.288 (0.636–2.609)

0.482

Pathologic T stage

  ≤ pT2

(reference)

   

  ≥ pT3

1.262 (0.599–2.659)

0.540

  

Pathologic N stage

 pN0, or pNx

(reference)

 

(reference)

 

 pN1

6.096 (1.316–28.234)

0.021

16.457 (3.358–80.652)

0.001

Tumor volume (%)

  < 10.0

(reference)

 

(reference)

 

  ≥ 10.0

3.888 (1.923–7.862)

< 0.001

4.137 (1.999–8.562)

< 0.001

Surgical margin tumor involvement

 Negative

(reference)

   

 Positive

1.678 (0.819–3.437)

0.157

  

Radiation dose (Gy)

  < 66.0

(reference)

   

  ≥ 66.0

1.564 (0.619–3.951)

0.344

  

Testosterone nadir after RP (ng/mL)

1.170 (0.834–1.643)

0.363

  

Duration of unrecovered testosterone level (months)

1.002 (0.989–1.015)

0.802

  

Concurrent ADT

 No

(reference)

   

 Yes

1.134 (0.563–2.287)

0.725

  

Salvage ADT

 No

(reference)

 

(reference)

 

 Yes

0.344 (0.171–0.692)

0.003

0.306 (0.150–0.627)

0.001

  1. HR hazard ratio, CI confidence interval, BMI body mass index, PSA prostate specific antigen, RP radical prostatectomy, ADT androgen deprivation therapy